AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platf ...

Core Insights - Younet.ai's Researgency.ai platform aims to revolutionize biotech R&D by applying autonomous research principles, validated by the recent release of AutoResearch by Andrej Karpathy [1][2][3] Group 1: AutoResearch and Its Implications - AutoResearch is an open-source tool that allows AI agents to autonomously conduct over 100 machine-learning experiments overnight on a single GPU, significantly increasing research velocity through continuous iteration [2][4] - The tool demonstrates the potential for autonomous research to transform life-sciences planning and decision-making, aligning with Younet.ai's vision for Researgency.ai [2][5] Group 2: Researgency.ai Development - Researgency.ai is being developed in collaboration with Kala Bio, Inc. (NASDAQ: KALA) to implement autonomous research loops in biotechnology R&D, translating the concept of "100 experiments overnight" into "100 study scenarios overnight" [5][10] - The platform is designed to enable agents to autonomously plan, simulate, and optimize research scenarios, thereby enhancing the efficiency of biotech research workflows [5][13] Group 3: The Agentic Research Loop - The agentic research loop consists of three phases: defining objectives with human input, executing autonomous agent loops for scenario generation and evaluation, and conducting morning reviews for strategic decision-making [6][8] - This approach aims to shift life-sciences organizations from manual, sequential planning to continuous, parallel scenario exploration, compressing timelines and expanding viable options [11][12] Group 4: Real-World Applications and Benefits - A public example from Shopify's CEO indicates that using AutoResearch led to a 19% improvement in validation scores, showcasing the effectiveness of autonomous iteration in real-world applications [9][10] - Younet.ai believes that agentic approaches can yield compounding improvements in complex optimization problems, which Researgency.ai seeks to apply in life-sciences contexts [10]

Core Insights - KALA BIO, Inc. is transitioning from a clinical-stage biotech to a dual-engine growth company with a proprietary drug pipeline and an AI platform targeting the $180+ billion AI-in-healthcare market [1][6] - The company is set to launch its first commercial AI product, Researgency.ai, within approximately 14 days, marking a significant step in its go-to-market strategy [2][8] Company Strategy - KALA aims to build a dedicated AI infrastructure for the biotech industry, similar to how Palantir operates in data analytics for various sectors [1][3] - The Researgency.ai platform is designed to address critical pain points in biotech and pharma, such as repetitive workflows, compliance documentation, and costly delays in drug development [4][5] Market Opportunity - The global AI-in-healthcare market is projected to exceed $180 billion by 2030, with a significant increase in enterprise interest in agentic AI systems, as evidenced by a 1,445% surge in inquiries from Q1 2024 to Q2 2025 [3] - KALA is focusing on the biotech and pharmaceutical sectors, which are characterized by high data intensity and compliance requirements, positioning itself as a key player in this niche market [3][4] Product Capabilities - The Researgency.ai platform will enable companies to design, deploy, and improve AI agents for various applications, including research intelligence, clinical trials, regulatory compliance, safety monitoring, and commercial launch preparations [5] Investor Implications - The transformation of KALA from a single-drug focus to a platform company with recurring revenue potential is expected to attract a broader range of investors, as it can now serve multiple clients in the biotech and pharma industries [6][8] - Early investors in successful platform companies have historically seen significant returns, indicating a promising outlook for KALA's future [7]

Group 1 - Stock Trend Capital Inc. has provided an update on its investment in Younet AI, a Canadian company focused on developing AI platforms for customized model building [1] - Younet AI has entered a strategic partnership with KALA BIO Inc., granting KALA BIO an exclusive worldwide license to Younet's AI research platform, "Researgency," for the biotechnology sector [2] - The CEO of Stock Trend Capital, Anthony Durkacz, expressed confidence in Younet's progress and its potential to enhance the value of Stock Trend's investment over time [3] Group 2 - Stock Trend Capital focuses on investments in sectors such as AI, crypto, mining, quantum technology, and the Canadian cannabis industry, targeting entities with strong intellectual property and high growth potential [4]

Financial Data and Key Metrics Changes - The preliminary voting results indicated that all proposals presented during the meeting received majority support from shareholders, reflecting a positive sentiment towards the company's governance and strategic direction [9][10][11] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed during the meeting, focusing instead on governance and shareholder proposals [3][4][5] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting, as the focus was primarily on the voting of proposals and board elections [2][3] Company Strategy and Development Direction - The company is looking to increase its authorized shares from 125 million to 1.5 billion, indicating a potential strategy for future capital raising or stock-based compensation [5] - The proposal for a reverse stock split suggests a strategic move to enhance the stock price and meet listing requirements [6] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting, as the focus was on procedural matters and shareholder voting [2][3] Other Important Information - The meeting included the election of Class II directors, approval of executive compensation, and the selection of an independent accounting firm, all of which passed with majority votes [9][10][11] Q&A Session Summary - There were no questions submitted by shareholders during the Q&A session, indicating either satisfaction with the proposals or a lack of engagement from the attendees [8][12]

Financial Data and Key Metrics Changes - The company reported preliminary voting results indicating that all nominees for Class II directors received a plurality of votes in favor of their election [9] - The majority of votes cast by holders of common stock were in favor of the proposals regarding executive compensation, selection of accounting firm, and issuance of shares [10][11] Business Line Data and Key Metrics Changes - No specific data or metrics regarding individual business lines were provided in the meeting [8] Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting [8] Company Strategy and Development Direction - The company is focused on increasing the number of authorized shares of common stock from 125 million to 1.5 billion, indicating a strategy to enhance capital flexibility [5] - The board recommended a reverse stock split at a ratio between 1-for-2 and 1-for-100, suggesting a strategic move to potentially increase share price and attract institutional investors [6] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting [8] Other Important Information - The meeting included seven items on the agenda, all of which were passed by majority votes [10][11] - The company plans to file a Form 8-K with the SEC to disclose final voting results [3] Q&A Session Summary - There were no questions submitted by stockholders during the meeting [8]

Financial Data and Key Metrics Changes - The meeting discussed the election of Class II directors and the approval of executive compensation, indicating a focus on governance and management structure [4][10] - The company proposed to increase the number of authorized shares from 125 million to 1.5 billion, reflecting a significant change in capital structure [5][10] Business Line Data and Key Metrics Changes - No specific data on business line performance or key metrics was provided in the meeting [7] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting [7] Company Strategy and Development Direction - The company is looking to authorize the issuance of shares upon conversion of preferred stock, which may indicate a strategy to enhance liquidity and capital [5][10] - A reverse stock split was proposed, which could be a strategy to increase the stock price and meet listing requirements [6][10] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [7] Other Important Information - The meeting included a voting process for several proposals, all of which passed, indicating shareholder support for the company's governance and capital structure changes [9][11] Q&A Session All Questions and Answers - No questions were raised during the Q&A session, indicating a lack of immediate concerns from shareholders [7][12]

Core Viewpoint - KALA BIO, Inc. has successfully completed a loan settlement with Oxford Finance, resolving critical debt obligations and marking a significant milestone for the company [1][3]. Debt Settlement - KALA and its subsidiary Combangio, Inc. entered into a Loan Settlement Agreement with Oxford, which involved a payment obligation of $2 million to settle approximately $10.6 million in debt as of December 26, 2025 [2][3]. - The completion of the $2 million payment has fully satisfied and discharged all obligations under both the Settlement Agreement and the underlying Loan Agreement [3]. Strategic Implications - The CEO of KALA BIO, David E. Lazar, stated that the settlement removes a substantial overhang that was constraining the company's strategic flexibility, thereby enhancing stockholders' equity and confidence in the company's future [4]. - Following the settlement, KALA granted common stock awards totaling 400,000 shares to four new employees as an inducement to employment, approved by the Compensation Committee of KALA's Board of Directors [4].

Group 1 - KALA BIO, Inc. announced the closing of a registered direct offering of 10,000,000 shares of common stock at a price of $1.00 per share, generating approximately $10 million in gross proceeds [1][2] - The company intends to use the net proceeds from the offering to repay certain indebtedness and for general corporate purposes [2] - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [1] Group 2 - The offering was conducted under a "shelf" registration statement filed with the SEC, which was declared effective on May 11, 2023 [3] - KALA is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases, utilizing its proprietary mesenchymal stem cell secretome platform [5] - The lead product candidate, KPI-012, has received Orphan Drug and Fast Track designations from the FDA for treating persistent corneal epithelial defect [5]

Core Viewpoint - KALA BIO, Inc. has announced a registered direct offering of 10,000,000 shares of its common stock at a price of $1.00 per share, aiming to raise approximately $10 million in gross proceeds for debt repayment and general corporate purposes [1][2]. Group 1: Offering Details - The offering is priced at-the-market under Nasdaq rules and is expected to close on or about December 5, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. - The net proceeds from the offering will be used to repay certain indebtedness and for general corporate purposes [2]. Group 2: Company Background - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and severe eye diseases [5]. - The company's lead product candidate, KPI-012, is based on its proprietary mesenchymal stem cell secretome platform and has received Orphan Drug and Fast Track designations from the FDA for treating persistent corneal epithelial defect [5].